Oncology Institute Inc (ticker: TOI) is a leading healthcare organization focused on revolutionizing cancer care through its extensive network of specialized clinics and innovative treatment methodologies. By harnessing advanced technologies and personalized care strategies, the company aims to significantly improve patient outcomes while emphasizing clinical trials and partnerships with premier research institutions. Positioned to capitalize on the growing demand for advanced cancer therapies, TOI benefits from a solid pipeline and a wealth of oncology expertise, presenting a compelling investment opportunity within the dynamic healthcare landscape.
| Revenue (TTM) | $545.76M |
| Gross Profit (TTM) | $82.50M |
| EBITDA | $-25.91M |
| Operating Margin | -4.42% |
| Return on Equity | -652.00% |
| Return on Assets | -12.30% |
| Revenue/Share (TTM) | $5.54 |
| Book Value | $-0.16 |
| Price-to-Book | 0.76 |
| Price-to-Sales (TTM) | 0.95 |
| EV/Revenue | 1.047 |
| EV/EBITDA | 8.53 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 41.20% |
| Shares Outstanding | $99.98M |
| Float | $87.24M |
| % Insiders | 18.22% |
| % Institutions | 45.71% |
Volatility is currently expanding
CERRITOS, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) a pioneer in value-based community oncology care, today announced that the company will release its second quarter 2026 financial results on Thursday, August 6, 2026, to be followed by a conference call the same day at 5:00 p.m.
One area of Wall Street that investors might want to start buying are strong, best-in-class, cheap stocks trading under $10 a share in July and throughout the rest of 2026.
CERRITOS, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, announced today that it has repaid its $86 Million senior secured convertible note with Deerfield Partners through a debt refinancing that includes new credit facilities from OrbiMed.
Tom Yeung here with your Sunday Digest . In the days following its IPO, Space Exploration Technologies Corp. ( SPCX ) surged 25%, rewarding early investors and turning its owner, Elon Musk, into a trillionaire.
The Oncology Institute (TOI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Tom Yeung here with your Sunday Digest . In 2025, two professors wanted to see whether ChatGPT made people less creative.
The average of price targets set by Wall Street analysts indicates a potential upside of 38.1% in The Oncology Institute (TOI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
TORONTO, May 31, 2026 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV: TOI), acting through its subsidiary TSS Europe B.V. (“TSS”), today submitted a revised non-binding indicative proposal to acquire ReadyTech Holdings Limited (ASX: RDY) (“ReadyTech”) by way of a scheme of arrangement for cash consideration of $2.00 per share (the “Scheme Consideration”), or in the alternative, an off-market takeover bid with a 50.1% minimum acceptance condition at a cash consideration of $1.75 per share (the "Takeover Consideration") (together, the "Revised Proposal")1. All references herein to currency are in Australian dollars.
CERRITOS, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Yale D.
Topicus.com Inc. (TOI:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TOI and any ticker you trade — then tracks every position and per-strategy win rate.
